Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 2Not yet recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Breast Neoplasms 10184Neoplasms 7810Carcinoma, Non-Small-Cell Lung 5760Prostatic Neoplasms 5024Colorectal Neoplasms 4606Lung Neoplasms 3725Leukemia, Myeloid, Acute 3102Neoplasm Metastasis 3083Multiple Myeloma 3082Pancreatic Neoplasms 2845Melanoma 2653Ovarian Neoplasms 2573Lymphoma 2571Carcinoma, Hepatocellular 2480Stomach Neoplasms 2330Recurrence 2230Head and Neck Neoplasms 2103Precursor Cell Lymphoblastic Leukemia-Lymphoma 2086Lymphoma, Non-Hodgkin 2058Leukemia 2013Brain Neoplasms 1905Glioblastoma 1797Colonic Neoplasms 1791Leukemia, Lymphocytic, Chronic, B-Cell 1771Rectal Neoplasms 1720Uterine Cervical Neoplasms 1693Squamous Cell Carcinoma of Head and Neck 1654Lymphoma, Follicular 1652Lymphoma, Large B-Cell, Diffuse 1597Carcinoma, Renal Cell 1577

Interventions

efatutazone 1Nivolumab 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Advanced Non-small Cell Lung Cancer (NSCLC) × Clear all
NCT07590531 2026-05-15

AMT-116 in Combination With Ivosidan in Patients With Lung Cancer

Multitude Therapeutics Inc.

Phase 1/2 Not yet recruiting
118 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer (NSCLC)

NCT02175017 2024-12-09

ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer

Ono Pharmaceutical Co., Ltd.

Phase 2 Completed
104 enrolled 21 charts
Thoracic

Advanced Non-small Cell Lung Cancer (NSCLC)

NCT01101334 2020-06-16

Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer

Daiichi Sankyo

Phase 2 Completed
90 enrolled 11 charts
Thoracic

Advanced Non-small Cell Lung Cancer (NSCLC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡